Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Auric Goldfinger's Short List -- Ignore unavailable to you. Want to Upgrade?

To: Sir Auric Goldfinger who wrote (8383)	10/29/2001 9:40:57 PM
From: Jane4IceCream	Read Replies (1) \| Respond to of 19428

Blast From The Past.... #reply-10263164 Jane

To: Sir Auric Goldfinger who wrote (8383)	10/30/2001 8:56:19 AM
From: RockyBalboa	Read Replies (1) \| Respond to of 19428

Small fish shorting idea, WFHC. Stock at 7.50, worth perhaps $1. Women First HealthCare, Inc. Reports Third Quarter Net Loss of $0.05 Per Share; 58% Improvement Over Prior Year SAN DIEGO, Oct. 30, 2001 (PRIMEZONE) -- Women First HealthCare, Inc. (Nasdaq:WFHC - news) today announced financial results for the third quarter and nine months ended September 30, 2001 that demonstrate continuing progress under the Company's new specialty pharmaceutical model and show significant improvement over last year's comparable periods. The Company reported a quarterly net loss of $1.1 million or $0.05 per share for the third quarter 2001, which is a 57.6% improvement over the $2.5 million or $0.15 per share loss reported in third quarter 2000. For the nine months ended September 30, 2001, the Company lost $3.5 million or $0.19 per share, an 83.5% improvement over last year's net loss of $21.2 million or $1.22 per share. The Company reported third quarter 2001 total net revenue of $5.9 million as compared to $7.4 million for third quarter 2000, a decrease of $1.5 million or 19.9%. Excluding $5.4 million in related party service revenue earned last year as a result of contract revisions with Ortho-McNeil Pharmaceutical, Inc., third quarter 2001 total net revenue was up over 200% from last year's third quarter. The plunge in consumer confidence in the wake of the September 11 terrorist attacks negatively impacted the Company's Consumer Division in third quarter 2001, while the Pharmaceutical Division revenue was unaffected. For the nine-month period ended September 30, 2001, total revenue decreased $2.1 million or 10.3% to $18.6 million compared to $20.7 million for the same period in 2000. Related party service revenue in the comparable 2000 period was $9.7 million; without this non-recurring revenue, the 2001 period was $7.5 million ahead of the prior year. Commenting on the results, Edward F. Calesa, chairman, president and CEO, said, ``We continue to be encouraged with our movement toward profitability. Pharmaceutical product revenues increased dramatically in 2001. Of particular note in third quarter 2001, we were able to raise net proceeds of $29.3 million in August in a private placement of common stock. We acquired rights to a development-stage prenatal vitamin softgel, which we expect to be available for sale toward the end of 2002. Esclim(tm) was selected by AdvancePCS to their highest priority drug list effective January 1, 2002. We are currently in the process of increasing our pharmaceutical sales force by 25%. We have completed three pharmaceutical product acquisitions so far in 2001. Finally, we started the year with two pharmaceutical products. Today we have five and the year is not over. We have both the capital and the commitment to acquire additional products. Because of this, we are evaluating the efficiency of our current business structure of three operating units to determine if it is well suited to our current and future operations.'' Charles M. Caporale, vice president and CFO, added, ``This year is not directly comparable to last year because of the significance of non-recurring, related party revenue in 2000. We have been able to reduce the drain of working capital so that the funds raised in the private placement can be earmarked for product acquisition and marketing initiatives. The private placement tripled stockholders' equity at September 30 from year-end.''